又有两家A股上市公司收到股票终止上市决定，6月10日进入退市整理期。 *ST鹏博(600804)公告称，公司于2025年5月30日收到上海证券交易所出具的自律监管决定 书，决定终止公司股票上市。终止上市的证券种类为人民币普通股，证券简称为*ST鹏博，证 券代码为600804。 上述自律监管决定书指出，因2023年度财务会计报告被出具无法表示意见的审计报告，*ST鹏 博股票自2024年5月6日起被实施退市风险警示。2025年4月29日，*ST鹏博提交并披露了2024 年年度报告，显示公司2024年度财务会计报告和内部控制报告均被出具无法表示意见的审计 报告。根据《上海证券交易所股票上市规则（2025年4月修订）》（简称《股票上市规则》） 第9.3.7条等规定，*ST鹏博股票触及终止上市条件。根据《股票上市规则》第9.1.10条、第 9.3.11条和第9.3.14条的规定，经上海证券交易所上市审核委员会审议，上海证券交易所决定 终止*ST鹏博股票上市。 *ST龙宇(603003)也公告，公司于2025年5月30日收到上海证券交易所出具的自律监管决定 书，决定终止公司股票上市。终止上市的证券种类为人民币普通股，证券 ...

Core Viewpoint - *ST Pengbo (stock code: 600804) is set to be delisted from the Shanghai Stock Exchange due to regulatory violations, with the delisting process commencing on June 10, 2025, and expected to conclude by June 30, 2025 [2][3]. Group 1: Regulatory Actions - The company received a self-regulatory decision from the Shanghai Stock Exchange on May 30, 2025, leading to its delisting [2]. - The China Securities Regulatory Commission (CSRC) issued a notice on March 28, 2024, detailing administrative penalties against *ST Pengbo for failing to disclose related party transactions and significant contracts, as well as for false records in annual reports from 2012 to 2022 [3]. Group 2: Financial Performance - The company's revenue for 2022, 2023, and 2024 was reported at 3.705 billion, 2.606 billion, and 1.877 billion RMB, reflecting year-on-year changes of -6.25%, -29.66%, and -27.99% respectively [4]. - The net profit attributable to shareholders for the same years was -454 million, -93.2455 million, and -885 million RMB, with year-on-year changes of 61.20%, 79.46%, and -848.74% respectively [4]. - The company's asset-liability ratios were 87.59%, 87.59%, and 101.20% for the years 2022, 2023, and 2024 [4]. Group 3: Legal and Investor Implications - Investors who suffered losses due to the company's misconduct can seek compensation if they purchased shares between April 12, 2013, and July 17, 2023, and still held them as of July 17, 2023 [3]. - The company has a significant number of legal risks, with 1,084 internal risks and 1,313 surrounding risks reported [5].

屋漏偏逢连夜雨。 *ST天喻（300205）今晚发布公告称，公司收到武汉市公安局送达的《立案告知书》，公司实际控制人之一闫春雨等人涉嫌挪 用资金案，武汉市公安局认为符合刑事案件立案标准，根据规定现已决定立案侦查。 公告显示，截至公告披露日，闫春雨未担任公司董事、监事、高级管理人员，上述事项不会对公司正常生产经营产生重大影 响。公司将积极配合公安机关调查并持续关注上述事项的进展情况，严格按照有关法律的规定和要求，及时履行信息披露义 务。 *ST天喻董事会强调，公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。公司将继续遵守相关法律法规，维护公司及全体股东的利益。 值得注意的是，近期*ST天喻的董事、高管密集辞职，其中包括公司董事长杨海涛、董事艾迪、副总经理兼财务负责人张艳菊 及副总经理兼董事会秘书万骏。 与此同时，*ST天喻还面临着退市风险。*ST天喻2024年度内部控制被出具否定意见的审计报告，公司股票交易已被叠加实施 其他风险警示。对此，*ST天喻表示，公司董事会高度重视，正在采取相应措施持续加强内部控制体系建设和审计监督，争取 尽快消除相关事项对公司的影响。 突 ...

Group 1 - The company *ST Weidi (603023)* has announced the cancellation of its delisting risk warning, with the stock being suspended for one day and set to resume trading on June 4, 2025 [1] - Following the cancellation, the stock's name will change to "Weidi Co., Ltd." and the daily price fluctuation limit will be adjusted to 10% [1] - For the fiscal year 2024, the company reported a net profit of 5.0555 million yuan, with a net profit of 4.1528 million yuan after deducting non-recurring gains and losses, both achieving positive values, which meets the conditions for the cancellation of the delisting risk warning [1]

Core Viewpoint - *ST Jinguang (SH600190) has received an administrative penalty from the Liaoning Securities Regulatory Bureau, totaling 38.6 million yuan due to multiple violations, including failure to disclose financial reports on time and false reporting of financial data [1][4][5]. Group 1: Violations Identified - The company failed to disclose its 2024 semi-annual report on time, with key executives held responsible [2]. - There were instances of false records in periodic reports from 2022 to 2024, where profits were inflated through fictitious trade activities and improper revenue recognition [2][3]. - The company did not timely disclose related party transactions, leading to significant omissions in periodic reports [3]. Group 2: Penalties Imposed - The Liaoning Securities Regulatory Bureau has mandated corrections, issued warnings, and imposed fines totaling 38.6 million yuan, with specific fines of 20 million yuan for the company and varying amounts for individual executives [4][5]. - Li Ting, the former vice president and CFO, received a 10-year ban from the securities market due to severe violations affecting market order and investor interests [5]. - Liu Hui, another key executive, is subject to separate legal proceedings for alleged violations related to the disclosure of important information [6]. Group 3: Regulatory Actions - The company has been notified by the Shanghai Stock Exchange regarding potential delisting due to long-term false reporting, which falls under the major illegal delisting criteria [6]. - The exchange has emphasized the importance of responsible conduct from all board members and executives in managing the delisting process and fulfilling disclosure obligations [6].

星标 ★ IPO日报 精彩文章第一时间推送 高度依赖单一产品 据悉，*ST龙津公司全称为昆明龙津药业股份有限公司，成立于1996年9月，于2015年在深交所挂牌上市。 公司聚焦于心脑血管疾病及代谢类疾病两大领域的治疗型药物的开发、研究、生产及销售，其主导产品为龙津注射用灯盏花素冻干粉针剂，该产品 2016年销量曾达到3569万支的峰值。 2015年—2017年，上市后前三年公司营收较为稳定，分别为1.81亿元、2.24亿元、3.04亿元，实现扣非净利润为0.54亿元、0.58亿元、0.19亿 元。 但在2018年之后，公司盈利状况急转直下，2019年至今，其扣非净利润始终为负值。 制图：李昕 根据2024年年报，*ST龙津全年营收0.66亿元，同比下滑23.25%，连续五年未达1亿元；净利润亏损0.41亿元，虽同比收窄41.58%，但扣非净利 润仍亏损0.5亿元。 这一数据直接触发深交所退市新规中"净利润为负且营收低于3亿元"的强制退市条款。 2025年5月29日，*ST龙津（002750.SZ）公告称，公司于2025年5月28日收到深交所送达的《关于昆明龙津药业股份有限公司股票终止上市的决 定》，深交所决定 ...

证券代码：600190/900952 证券简称：*ST 锦港/*ST 锦港 B 公告编号：2025-071 锦州港股份有限公司 关于收到上海证券交易所《关于对公司实施重大违法 强制退市相关事项的监管工作函》的公告 （〔2025〕 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 锦州港股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日收到上海证 券交易所下发的《关于对公司实施重大违法强制退市相关事项的监管工作函》 $$(\bot\vdash\bot$$ 证公函【2025】0702 号），具体内容如下： "锦州港股份有限公司 定书》（〔2025〕3号），认定公司《2022年年度报告》《2023年年度报告》《2024 年第一季度报告》存在虚假记载。此外，2024年11月1日，公司公告收到中国证 监会《行政处罚决定书》(〔2024〕96 号)，认定公司2018年至2021年年度报告 虚假记载。根据《行政处罚决定书》(〔2024〕96 号)、 《行政处罚决定书》 特此公告。 锦州港股份有限公司董事会 及《上海证券交易所股 ...

Group 1 - The core point of the article is that Jiyuan Holdings Group Co., Ltd. (*ST Jiyuan) will be delisted from the Shenzhen Stock Exchange on May 29, 2025, due to triggering mandatory delisting rules after its stock price remained below 1 yuan for 20 consecutive trading days [1][3] - The company has experienced continuous losses since 2019, with a cumulative net profit loss exceeding 3.2 billion yuan from 2019 to 2023 [3] - Jiyuan Holdings has faced significant goodwill impairment risks, totaling over 1.5 billion yuan from 2019 to 2024, which has directly contributed to its net profit losses [3] Group 2 - The company was originally known as Tonghua Shuanglong Chemical Co., Ltd. and transitioned to the pharmaceutical sector in 2014 through the acquisition of Jinbao Pharmaceutical [3] - Since its rebranding in 2017, the company has aggressively pursued mergers and acquisitions, acquiring over ten companies within three years, leading to a dual business model of "chemicals + pharmaceuticals" [3] - In 2024, the company's revenue declined by 3.69%, and its losses expanded to 439 million yuan [3] Group 3 - As of 2025, a total of 11 companies have been delisted from the A-share market, with *ST Jiyuan being one of them, alongside others like *ST Meixun and *ST Bo Xin [4] - The reasons for delisting include breaches of face value, market value, voluntary delisting applications, and forced delisting due to major violations [4]

Core Viewpoint - Jiyuan Holdings Group Co., Ltd. has been announced to be delisted from the Shenzhen Stock Exchange due to its stock price falling below 1 yuan for twenty consecutive trading days, with the delisting effective on May 29, 2025 [1] Group 1: Company Performance and Financials - Jiyuan Holdings, originally a chemical company, transitioned to the pharmaceutical sector in 2014 through the acquisition of Jinbao Pharmaceutical, establishing a dual business model of "chemicals + pharmaceuticals" [3] - The company engaged in aggressive acquisitions, acquiring over ten companies within three years, with its pharmaceutical segment accounting for 70% of total revenue at its peak, leading to a market capitalization exceeding 5 billion yuan [3] - However, the acquired companies' performance deteriorated post-acquisition, with Zhejiang Yalida Gelatin Co., Ltd. reporting a 94% drop in net profit in 2019, and Changchun Puhua Pharmaceutical Co., Ltd. incurring direct losses [3] - Since 2019, Jiyuan Holdings has been in a continuous loss state, accumulating losses exceeding 3.7 billion yuan [4] Group 2: Attempts at Restructuring and Ownership Changes - The company has made several attempts to change ownership in response to its financial struggles, but all efforts have failed [5] - In 2019, an agreement to transfer shares to Jilin Jisheng Asset Management was terminated due to disagreements on key terms [5] - A proposed acquisition of Xiu Zheng Pharmaceutical was also abandoned due to regulatory uncertainties, leading to scrutiny from the Shenzhen Stock Exchange [5][6] - In 2020, a deal to transfer control to Ben Cao Hui Pharmaceutical faced disputes over payment, resulting in legal proceedings [6]

金科股份 2024 年度业绩说明会会议纪要 公司 2024 年度业绩说明会首先由公司董事长介绍公司司法重整进展，再由 董事会秘书简要介绍 2024 年经营情况，具体内容与公司重整进展公告及 2024 年年度报告第三节管理层讨论与分析中的"报告期公司主要经营情况总结与分 析"保持一致。 证券代码：000656 证券简称：*ST 金科 金科地产集团股份有限公司投资者关系活动记录表 编号：2025-01 | | □特定对象调研 □分析师会议 | | | --- | --- | --- | | | □媒体采访 ☑业绩说明会 | | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | | | 参与单位名称及 | | | | 人员姓名 | 线上参与公司 2024 年度网上业绩说明会的投资者 | | | 时间 | 2025 5 月 29 日（星期四）16:00-17:00 | 年 | | 地点 | 通过"全景网"线上直播 | | | 上市公司接待人 | 公司董事长、总裁、财务负责人、董事会秘书及产业投资人代 | | | 员姓名 | | | | 投资者关系活动 | ...